文献速递慢性肾脏病血液净化与透析

阿片类药物与非甾体抗炎药在CKD中的结局关联:CRIC研究

Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study.
PubMed 文献 · Am J Kidney Dis · 2020-04-18

本研究为前瞻性队列研究,纳入3939例慢性肾脏病患者,比较阿片类与非甾体抗炎药(NSAID)使用与肾脏及全身不良结局的关联。中位随访6.84年,阿片类使用与肾脏复合结局、肾衰竭需肾脏替代治疗、死亡及住院风险升高相关;NSAID使用与肾脏复合结局和住院风险轻度相关,且风险因种族和性别等亚组而异。

要点

  • 阿片类使用与肾脏复合结局、肾衰竭需KRT、死亡及住院风险升高相关。
  • NSAID使用与肾脏复合结局风险轻度升高相关,尤其在黑人中显著。
  • 女性及GFR<45mL/min/1.73m2者使用NSAID与肾衰竭需KRT风险降低相关。

核心结论

  • 阿片类使用与不良事件关联强于NSAID,NSAID与肾脏结局关联限于特定亚组(尤其黑人)。

研究设计与样本

  • 前瞻性队列研究,纳入慢性肾功能不全队列(CRIC)中3939例CKD患者。
  • 暴露为每年访视时报告的30天镇痛药使用,采用边际结构模型分析时间更新暴露。

主要发现

  • 中位随访6.84年,基线阿片类使用391例(9.9%),NSAID使用612例(15.5%)。
  • 时间更新阿片类使用与肾脏复合结局(HR 1.4,95%CI 1.2-1.7)、肾衰竭需KRT(HR 1.4,95%CI 1.1-1.7)、死亡(HR 1.5,95%CI 1.2-2.0)及住院(RR 1.7,95%CI 1.6-1.9)相关。
  • 时间更新NSAID使用与肾脏复合结局(HR 1.2,95%CI 1.0-1.5)及住院(RR 1.1,95%CI 1.0-1.3)相关,但亚队列中不显著。
  • NSAID与肾脏复合结局关联因种族而异,黑人中风险显著(HR 1.3,95%CI 1.0-1.7)。
  • 女性及GFR<45mL/min/1.73m2者使用NSAID与肾衰竭需KRT风险降低相关(HR 0.63,95%CI 0.45-0.88;HR 0.77,95%CI 0.59-0.99)。

临床怎么用

  • CKD患者应优先避免阿片类镇痛药,因其与肾脏及全身不良结局强相关。
  • NSAID在CKD中并非绝对禁忌,但需警惕黑人等特定亚组的肾脏风险。

局限性

  • 镇痛药使用回忆期有限,可能存在指征混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Safe analgesic choices are limited in chronic kidney disease (CKD). We conducted a comparative analysis of harm from opioids versus nonsteroidal anti-inflammatory drugs (NSAIDs) in CKD. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 3,939 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. EXPOSURES: 30-day analgesic use reported at annual visits. OUTCOMES: A composite outcome of 50% glomerular filtration rate reduction and kidney failure requiring kidney replacement therapy (KRT), as well as the outcomes of kidney failure requiring KRT, hospitalization, and pre-kidney failure death. ANALYTICAL APPROACH: Marginal structural models with time-updated exposures. RESULTS: Participants were followed up for a median of 6.84 years, with 391 (9.9%) and 612 (15.5%) reporting baseline opioid and NSAID use, respectively. Time-updated opioid use was associated with the kidney disease composite outcome, kidney failure with KRT, death (HRs of 1.4 [95% CI, 1.2-1.7], 1.4 [95% CI, 1.1-1.7], and 1.5 [95% CI, 1.2-2.0], respectively), and hospitalization (rate ratio [RR], 1.7; 95% CI, 1.6-1.9) versus opioid nonusers. Similar results were found in an analysis restricted to a subcohort of participants reporting ever using other (nonopioid and non-NSAID) analgesics or tramadol. Time-updated NSAID use was associated with increased risk for the kidney disease composite (HR, 1.2; 95% CI, 1.0-1.5) and hospitalization (RR, 1.1; 95% CI, 1.0-1.3); however, these associations were not significant in the subcohort. The association of NSAID use with the kidney disease composite outcome varied by race, with a significant risk in blacks (HR, 1.3; 95% CI, 1.0-1.7). NSAID use was associated with lower risk for kidney failure with KRT in women and individuals with glomerular filtration rate<45mL/min/1.73m2 (HRs of 0.63 [95% CI, 0.45-0.88] and 0.77 [95% CI, 0.59-0.99], respectively). LIMITATIONS: Limited periods of recall of analgesic use and potential confounding by indication. CONCLUSIONS: Opioid use had a stronger association with adverse events than NSAIDs, with the latter's association with kidney disease outcomes limited to specific subgroups, notably those of black race.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Zhan M, Doerfler RM, Xie D, et al. Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2020. PMID: 32317121. doi:10.1053/j.ajkd.2019.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。